Oppenheimer initiated coverage on TriSalus Life Sciences with a new price target
$TLSI
Medical Specialities
Health Care
Oppenheimer initiated coverage of TriSalus Life Sciences with a rating of Outperform and set a new price target of $10.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/11/2024 | $11.00 | Buy | ROTH MKM |
| 10/25/2024 | $12.50 | Outperform | Northland Capital |
| 9/16/2024 | $10.00 | Outperform | Oppenheimer |
| 5/30/2024 | $12.00 | Buy | Canaccord Genuity |
ROTH MKM initiated coverage of TriSalus Life Sciences with a rating of Buy and set a new price target of $11.00
Northland Capital initiated coverage of TriSalus Life Sciences with a rating of Outperform and set a new price target of $12.50
Oppenheimer initiated coverage of TriSalus Life Sciences with a rating of Outperform and set a new price target of $10.00
– Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year – Provided 2025 guidance with expectations of over 50% annual sales growth, 20%+ reduction in operating expenses, positive full-year EBITDA, and positive cash flow in H2 2025 – Launched TriNav® LV Infusion System and TriGuide™ Guiding Catheter for larger vessels and complex cases, expanding the TriNav system's full access to the $375 million embolization market – Initiated the PROTECT registry trial using the TriNav system to treat multinodular goiters, expanding the TriNav system's reach into the $400 million thyroid embolization market – Presented positive Phase 1 da
TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), an oncology company dedicated to enhancing outcomes for patients suffering from liver cancer through its advanced delivery technology as well as an investigational immunotherapy, nelitolimod, has announced a strategic partnership with Geo-Med, LLC ("Geo-Med"), a certified Service-Disabled Veteran-Owned Small Business (SDVOSB), to expand availability of the TriNav Infusion System ("TriNav") to U.S. Department of Veterans Affairs (VA) medical centers nationwide. "Fittingly, on the day honoring our veterans, we announce this pivotal collaboration designed to expand access for U.S. veterans to our proprietary Pressure-En
TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), a leader in oncology innovations integrating advanced delivery technology to transform treatment for liver and pancreatic tumors, today announced the launch of the TriNav® LV Infusion System and TriGuide™ Guiding Catheter. These new devices are designed to optimize therapeutic delivery, enhancing treatment options and potentially improving outcomes for patients. Highlights of the Launch: Expanded Patient Access: The TriNav LV Infusion System is tailored for larger vessels (3.5-5.0 mm), increasing the number of patients eligible for TriSalus' proprietary Pressure-Enabled Drug Delivery (PEDD™) technology. Comprehen
SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
– Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year – Provided 2025 guidance with expectations of over 50% annual sales growth, 20%+ reduction in operating expenses, positive full-year EBITDA, and positive cash flow in H2 2025 – Launched TriNav® LV Infusion System and TriGuide™ Guiding Catheter for larger vessels and complex cases, expanding the TriNav system's full access to the $375 million embolization market – Initiated the PROTECT registry trial using the TriNav system to treat multinodular goiters, expanding the TriNav system's reach into the $400 million thyroid embolization market – Presented positive Phase 1 da
Call Scheduled for Thursday, November 14, 2024, at 9:00 a.m. ET TriSalus Life Sciences® Inc., (NASDAQ:TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today it will host a conference call and webcast on November 14, 2024, at 9:00 a.m. ET to discuss financial results for the third quarter ended September 30, 2024, and provide a business update. A press release detailing the third quarter results will be issued prior to the call. The event will be webcast live on the investor relations section of TriSalus' website at https://investors.trisaluslifes
Reported revenues of $7.4 million in Q2 2024 and $13.8 million for six months ended June 30, 2024, up 60% and 82%, respectively, compared to prior year periods Reported gross margin of 88% in Q2 2024 and 86% for the six months ended June 30, 2024, compared to 83% and 81%, respectively, in the prior year periods Announces plan to launch the "DELIVER" Program in Q3 2024, clinical trials leveraging the TriNav® Infusion System (TriNav) in complex patient types and aiming to significantly expand the addressable market Expects to report data from phase 1 trials of nelitolimod in uveal melanoma liver metastases and locally advanced pancreatic cancer via its pancreatic infusion technol
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
10-Q - TriSalus Life Sciences, Inc. (0001826667) (Filer)
8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)
EFFECT - TriSalus Life Sciences, Inc. (0001826667) (Filer)
TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, has announced the addition of Riad Salem, M.D., to its Scientific Advisory Board (SAB). Dr. Salem is the Chief of Interventional Radiology, and a Professor of Radiology, Surgery, and Medicine in Chicago. Mary Szela, Chief Executive Officer and President of TriSalus, stated, "We are thrilled to welcome Dr. Salem to our SAB. His pioneering work in radiological research and leadership in developing innovative treatments for liver cancer and other
– Accomplished industry veteran brings deep strategic and operational expertise TriSalus Life Sciences® Inc. (NASDAQ:TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the appointment of Liselotte Hyveled to its Board of Directors. Ms. Hyveled brings over two decades of experience stimulating scientific innovation and advancing pharmaceutical pipelines through research and development excellence. "We are thrilled to welcome Liselotte to the TriSalus Board of Directors as we commercialize the TriNav® Infusion System and progress our pipeline through key milestones in
Devlin Brings Significant Expertise in Commercialization, Sales and Marketing TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced that Jodi Devlin has joined the Company as President of TriSalus Therapeutics. In this newly established role, Ms. Devlin will be responsible for developing and executing the go-to-market strategy for TriSalus' SD-101 therapeutic candidate, building the Company's therapeutic marketing operations, working with the clinical team to incorporate commercial and payor needs into the clinical stra
Canaccord Genuity analyst William Plovanic maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and maintains $12 price target.
TriSalus Life Sciences, Inc. (NASDAQ:TLSI), an oncology company integrating its novel Pressure Enabled Drug Delivery™ (PEDD™) technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced that data from its Phase 1b PERIO-02 clinical trial was presented in a poster session at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024, in Chicago, Illinois. The PEDD approach is a proprietary delivery mechanism developed by TriSalus that aims to overcome challenges of the tumor microenvironment (TME) by modulating pressure and flow to enhance local drug concentrations in tumors by improving intra
Canaccord Genuity analyst William Plovanic initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and announces Price Target of $12.